25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ANAB (Anaptysbio) Stock Analysis
Buy, Hold or Sell?

Let's analyze Anaptysbio together

I guess you are interested in AnaptysBio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Anaptysbio’s Financial Insights
  • 📈 Technical Analysis (TA) – Anaptysbio’s Price Targets

I'm going to help you getting a better view of AnaptysBio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AnaptysBio Inc

I send you an email if I find something interesting about AnaptysBio Inc.

1. Quick Overview

1.1. Quick analysis of Anaptysbio (30 sec.)










1.2. What can you expect buying and holding a share of Anaptysbio? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$1.11
Expected worth in 1 year
$0.59
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.52
Return On Investment
-2.3%

For what price can you sell your share?

Current Price per Share
$22.65
Expected price per share
$19.04 - $26.51
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Anaptysbio (5 min.)




Live pricePrice per Share (EOD)
$22.65
Intrinsic Value Per Share
$-31.00 - $4.16
Total Value Per Share
$-29.89 - $5.27

2.2. Growth of Anaptysbio (5 min.)




Is Anaptysbio growing?

Current yearPrevious yearGrowGrow %
How rich?$34m$101.1m-$51.3m-103.2%

How much money is Anaptysbio making?

Current yearPrevious yearGrowGrow %
Making money-$35.1m-$40.8m$5.6m16.1%
Net Profit Margin-181.7%-839.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Anaptysbio (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#458 / 884

Most Revenue
#200 / 884

Most Profit
#734 / 884

Most Efficient
#568 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Anaptysbio?

Welcome investor! Anaptysbio's management wants to use your money to grow the business. In return you get a share of Anaptysbio.

First you should know what it really means to hold a share of Anaptysbio. And how you can make/lose money.

Speculation

The Price per Share of Anaptysbio is $22.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anaptysbio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anaptysbio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.11. Based on the TTM, the Book Value Change Per Share is $-0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anaptysbio.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.28-5.7%-1.18-5.2%-1.39-6.1%-1.25-5.5%-0.93-4.1%-0.64-2.8%
Usd Book Value Change Per Share-1.30-5.7%-0.13-0.6%-1.22-5.4%-0.85-3.7%-0.63-2.8%0.020.1%
Usd Dividend Per Share0.000.0%0.000.0%0.020.1%0.010.0%0.010.0%0.000.0%
Usd Total Gains Per Share-1.30-5.7%-0.13-0.6%-1.20-5.3%-0.83-3.7%-0.62-2.7%0.030.1%
Usd Price Per Share18.59-22.60-20.56-22.60-23.19-29.62-
Price to Earnings Ratio-3.62--4.88--3.69--4.73--27.98--19.04-
Price-to-Total Gains Ratio-14.28--12.33--17.37--19.78--27.88--71.33-
Price to Book Ratio16.74-27.11-7.35-12.44-8.23-5.96-
Price-to-Total Gains Ratio-14.28--12.33--17.37--19.78--27.88--71.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share22.65
Number of shares44
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.13-0.63
Usd Total Gains Per Share-0.13-0.62
Gains per Quarter (44 shares)-5.68-27.26
Gains per Year (44 shares)-22.70-109.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-23-331-110-119
20-45-562-220-228
30-68-793-331-337
40-91-1025-441-446
50-114-1256-551-555
60-136-1487-661-664
70-159-1718-771-773
80-182-1949-882-882
90-204-21710-992-991
100-227-24012-1102-1100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.037.00.07.5%6.039.01.013.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%9.031.00.022.5%12.031.03.026.1%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.044.04.3%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%9.031.00.022.5%12.031.03.026.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AnaptysBio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.302-0.129-90%-1.219-6%-0.846-35%-0.626-52%0.022-6047%
Book Value Per Share--1.1101.683-34%3.444-68%4.645-76%7.853-86%7.841-86%
Current Ratio--8.2469.266-11%10.964-25%12.873-36%16.629-50%14.603-44%
Debt To Asset Ratio--0.9190.895+3%0.788+17%0.750+23%0.516+78%0.342+169%
Debt To Equity Ratio--11.40616.086-29%4.290+166%7.244+57%4.452+156%2.380+379%
Dividend Per Share----0%0.019-100%0.011-100%0.007-100%0.003-100%
Enterprise Value--521575960.000639468965.000-18%636604580.000-18%700678355.000-26%831815050.000-37%1257820364.697-59%
Eps---1.283-1.183-8%-1.390+8%-1.245-3%-0.927-28%-0.635-51%
Ev To Ebitda Ratio---4.735-12.074+155%-4.520-5%-8.130+72%29.639-116%1.314-460%
Ev To Sales Ratio--4.6957.605-38%32.985-86%53.745-91%69.612-93%85.156-94%
Free Cash Flow Per Share---0.350-0.866+147%-1.200+243%-0.909+159%-0.661+89%-0.476+36%
Free Cash Flow To Equity Per Share---1.2830.039-3401%-1.442+12%-0.683-47%-0.087-93%0.286-549%
Gross Profit Margin--1.0001.0020%1.0030%1.0020%1.0010%1.0000%
Intrinsic Value_10Y_max--4.155----------
Intrinsic Value_10Y_min---31.002----------
Intrinsic Value_1Y_max---1.571----------
Intrinsic Value_1Y_min---3.569----------
Intrinsic Value_3Y_max---3.205----------
Intrinsic Value_3Y_min---10.386----------
Intrinsic Value_5Y_max---3.013----------
Intrinsic Value_5Y_min---16.782----------
Market Cap665468325.000+14%569671960.000669797965.000-15%604063080.000-6%665932188.333-14%682611050.000-17%870793550.875-35%
Net Profit Margin---1.416-1.817+28%-8.392+493%-11.630+721%-10.758+660%-6.061+328%
Operating Margin---1.013-1.237+22%-7.386+629%-9.159+804%-8.735+762%-5.029+396%
Operating Ratio--1.9922.417-18%9.283-79%11.179-82%11.831-83%7.787-74%
Pb Ratio20.402+18%16.74527.107-38%7.350+128%12.442+35%8.230+103%5.964+181%
Pe Ratio-4.412-22%-3.621-4.880+35%-3.694+2%-4.725+30%-27.980+673%-19.042+426%
Price Per Share22.650+18%18.59022.598-18%20.560-10%22.599-18%23.194-20%29.619-37%
Price To Free Cash Flow Ratio-16.164-22%-13.267-12.948-2%-4.430-67%-9.468-29%-7.771-41%-18.718+41%
Price To Total Gains Ratio-17.398-22%-14.279-12.328-14%-17.371+22%-19.778+39%-27.883+95%-71.325+399%
Quick Ratio--13.60515.020-9%20.246-33%22.835-40%25.074-46%21.825-38%
Return On Assets---0.093-0.078-16%-0.089-5%-0.077-18%-0.057-39%-0.047-49%
Return On Equity---1.156-1.644+42%-0.494-57%-0.764-34%-0.474-59%-0.259-78%
Total Gains Per Share---1.302-0.129-90%-1.201-8%-0.835-36%-0.620-52%0.025-5270%
Usd Book Value--34021000.00049783750.000-32%101178500.000-66%136580833.333-75%230791850.000-85%230415550.000-85%
Usd Book Value Change Per Share---1.302-0.129-90%-1.219-6%-0.846-35%-0.626-52%0.022-6047%
Usd Book Value Per Share--1.1101.683-34%3.444-68%4.645-76%7.853-86%7.841-86%
Usd Dividend Per Share----0%0.019-100%0.011-100%0.007-100%0.003-100%
Usd Enterprise Value--521575960.000639468965.000-18%636604580.000-18%700678355.000-26%831815050.000-37%1257820364.697-59%
Usd Eps---1.283-1.183-8%-1.390+8%-1.245-3%-0.927-28%-0.635-51%
Usd Free Cash Flow---10735000.000-25552500.000+138%-35271000.000+229%-26743250.000+149%-19440050.000+81%-13999550.000+30%
Usd Free Cash Flow Per Share---0.350-0.866+147%-1.200+243%-0.909+159%-0.661+89%-0.476+36%
Usd Free Cash Flow To Equity Per Share---1.2830.039-3401%-1.442+12%-0.683-47%-0.087-93%0.286-549%
Usd Market Cap665468325.000+14%569671960.000669797965.000-15%604063080.000-6%665932188.333-14%682611050.000-17%870793550.875-35%
Usd Price Per Share22.650+18%18.59022.598-18%20.560-10%22.599-18%23.194-20%29.619-37%
Usd Profit---39329000.000-35156000.000-11%-40825000.000+4%-37788500.000-4%-28184400.000-28%-19257500.000-51%
Usd Revenue--27771000.00027968000.000-1%5740500.000+384%12127083.333+129%13483500.000+106%8695700.000+219%
Usd Total Gains Per Share---1.302-0.129-90%-1.201-8%-0.835-36%-0.620-52%0.025-5270%
 EOD+5 -3MRQTTM+12 -26YOY+15 -253Y+11 -295Y+10 -3010Y+9 -31

3.3 Fundamental Score

Let's check the fundamental score of AnaptysBio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.412
Price to Book Ratio (EOD)Between0-120.402
Net Profit Margin (MRQ)Greater than0-1.416
Operating Margin (MRQ)Greater than0-1.013
Quick Ratio (MRQ)Greater than113.605
Current Ratio (MRQ)Greater than18.246
Debt to Asset Ratio (MRQ)Less than10.919
Debt to Equity Ratio (MRQ)Less than111.406
Return on Equity (MRQ)Greater than0.15-1.156
Return on Assets (MRQ)Greater than0.05-0.093
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of AnaptysBio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.241
Ma 20Greater thanMa 5023.074
Ma 50Greater thanMa 10021.692
Ma 100Greater thanMa 20019.548
OpenGreater thanClose22.020
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Fundamental data was last updated by Penke on 2025-06-18 23:17:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Anaptysbio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • A Net Profit Margin of -141.6% means that $-1.42 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AnaptysBio Inc:

  • The MRQ is -141.6%. The company is making a huge loss. -2
  • The TTM is -181.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-141.6%TTM-181.7%+40.1%
TTM-181.7%YOY-839.2%+657.5%
TTM-181.7%5Y-1,075.8%+894.0%
5Y-1,075.8%10Y-606.1%-469.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-141.6%-92.7%-48.9%
TTM-181.7%-141.4%-40.3%
YOY-839.2%-186.1%-653.1%
3Y-1,163.0%-248.3%-914.7%
5Y-1,075.8%-338.6%-737.2%
10Y-606.1%-488.9%-117.2%
4.3.1.2. Return on Assets

Shows how efficient Anaptysbio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • -9.3% Return on Assets means that Anaptysbio generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AnaptysBio Inc:

  • The MRQ is -9.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.3%TTM-7.8%-1.5%
TTM-7.8%YOY-8.9%+1.0%
TTM-7.8%5Y-5.7%-2.2%
5Y-5.7%10Y-4.7%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.3%-11.5%+2.2%
TTM-7.8%-11.6%+3.8%
YOY-8.9%-11.4%+2.5%
3Y-7.7%-11.8%+4.1%
5Y-5.7%-12.1%+6.4%
10Y-4.7%-13.8%+9.1%
4.3.1.3. Return on Equity

Shows how efficient Anaptysbio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • -115.6% Return on Equity means Anaptysbio generated $-1.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AnaptysBio Inc:

  • The MRQ is -115.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -164.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-115.6%TTM-164.4%+48.8%
TTM-164.4%YOY-49.4%-115.0%
TTM-164.4%5Y-47.4%-117.0%
5Y-47.4%10Y-25.9%-21.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-115.6%-13.6%-102.0%
TTM-164.4%-14.9%-149.5%
YOY-49.4%-14.4%-35.0%
3Y-76.4%-17.0%-59.4%
5Y-47.4%-17.9%-29.5%
10Y-25.9%-20.1%-5.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AnaptysBio Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Anaptysbio is operating .

  • Measures how much profit Anaptysbio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • An Operating Margin of -101.3% means the company generated $-1.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AnaptysBio Inc:

  • The MRQ is -101.3%. The company is operating very inefficient. -2
  • The TTM is -123.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-101.3%TTM-123.7%+22.4%
TTM-123.7%YOY-738.6%+614.8%
TTM-123.7%5Y-873.5%+749.8%
5Y-873.5%10Y-502.9%-370.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-101.3%-229.2%+127.9%
TTM-123.7%-250.3%+126.6%
YOY-738.6%-205.1%-533.5%
3Y-915.9%-220.2%-695.7%
5Y-873.5%-342.6%-530.9%
10Y-502.9%-475.5%-27.4%
4.3.2.2. Operating Ratio

Measures how efficient Anaptysbio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.99 means that the operating costs are $1.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AnaptysBio Inc:

  • The MRQ is 1.992. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.417. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.992TTM2.417-0.426
TTM2.417YOY9.283-6.866
TTM2.4175Y11.831-9.413
5Y11.83110Y7.787+4.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9922.110-0.118
TTM2.4172.704-0.287
YOY9.2833.063+6.220
3Y11.1793.576+7.603
5Y11.8314.713+7.118
10Y7.7876.512+1.275
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AnaptysBio Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Anaptysbio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.25 means the company has $8.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AnaptysBio Inc:

  • The MRQ is 8.246. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.266. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.246TTM9.266-1.021
TTM9.266YOY10.964-1.697
TTM9.2665Y16.629-7.363
5Y16.62910Y14.603+2.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.2463.661+4.585
TTM9.2663.786+5.480
YOY10.9644.121+6.843
3Y12.8734.680+8.193
5Y16.6295.765+10.864
10Y14.6036.150+8.453
4.4.3.2. Quick Ratio

Measures if Anaptysbio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • A Quick Ratio of 13.60 means the company can pay off $13.60 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AnaptysBio Inc:

  • The MRQ is 13.605. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.020. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.605TTM15.020-1.415
TTM15.020YOY20.246-5.226
TTM15.0205Y25.074-10.054
5Y25.07410Y21.825+3.248
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6052.826+10.779
TTM15.0203.128+11.892
YOY20.2463.782+16.464
3Y22.8354.304+18.531
5Y25.0745.703+19.371
10Y21.8256.454+15.371
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AnaptysBio Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Anaptysbio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anaptysbio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.92 means that Anaptysbio assets are financed with 91.9% credit (debt) and the remaining percentage (100% - 91.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AnaptysBio Inc:

  • The MRQ is 0.919. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.895. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.919TTM0.895+0.025
TTM0.895YOY0.788+0.106
TTM0.8955Y0.516+0.379
5Y0.51610Y0.342+0.173
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9190.324+0.595
TTM0.8950.347+0.548
YOY0.7880.327+0.461
3Y0.7500.339+0.411
5Y0.5160.349+0.167
10Y0.3420.382-0.040
4.5.4.2. Debt to Equity Ratio

Measures if Anaptysbio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anaptysbio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1,140.6% means that company has $11.41 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AnaptysBio Inc:

  • The MRQ is 11.406. The company is unable to pay all its debts with equity. -1
  • The TTM is 16.086. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ11.406TTM16.086-4.680
TTM16.086YOY4.290+11.796
TTM16.0865Y4.452+11.633
5Y4.45210Y2.380+2.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.4060.383+11.023
TTM16.0860.436+15.650
YOY4.2900.410+3.880
3Y7.2440.446+6.798
5Y4.4520.460+3.992
10Y2.3800.509+1.871
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anaptysbio generates.

  • Above 15 is considered overpriced but always compare Anaptysbio to the Biotechnology industry mean.
  • A PE ratio of -3.62 means the investor is paying $-3.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AnaptysBio Inc:

  • The EOD is -4.412. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.621. Based on the earnings, the company is expensive. -2
  • The TTM is -4.880. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.412MRQ-3.621-0.791
MRQ-3.621TTM-4.880+1.259
TTM-4.880YOY-3.694-1.186
TTM-4.8805Y-27.980+23.100
5Y-27.98010Y-19.042-8.938
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.412-2.197-2.215
MRQ-3.621-2.027-1.594
TTM-4.880-2.527-2.353
YOY-3.694-3.733+0.039
3Y-4.725-3.717-1.008
5Y-27.980-6.036-21.944
10Y-19.042-6.649-12.393
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AnaptysBio Inc:

  • The EOD is -16.164. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.267. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.948. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.164MRQ-13.267-2.897
MRQ-13.267TTM-12.948-0.319
TTM-12.948YOY-4.430-8.518
TTM-12.9485Y-7.771-5.177
5Y-7.77110Y-18.718+10.948
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.164-3.007-13.157
MRQ-13.267-2.704-10.563
TTM-12.948-3.627-9.321
YOY-4.430-4.334-0.096
3Y-9.468-5.070-4.398
5Y-7.771-8.532+0.761
10Y-18.718-9.305-9.413
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Anaptysbio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 16.74 means the investor is paying $16.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AnaptysBio Inc:

  • The EOD is 20.402. Based on the equity, the company is expensive. -2
  • The MRQ is 16.745. Based on the equity, the company is expensive. -2
  • The TTM is 27.107. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD20.402MRQ16.745+3.657
MRQ16.745TTM27.107-10.363
TTM27.107YOY7.350+19.757
TTM27.1075Y8.230+18.877
5Y8.23010Y5.964+2.266
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.4021.921+18.481
MRQ16.7451.843+14.902
TTM27.1072.113+24.994
YOY7.3502.467+4.883
3Y12.4422.541+9.901
5Y8.2303.666+4.564
10Y5.9644.311+1.653
4.6.2. Total Gains per Share

2.4. Latest News of AnaptysBio Inc

Does AnaptysBio Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from AnaptysBio Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-04
20:49
J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agentRead
2025-06-03
22:05
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RARead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AnaptysBio Inc.

4.8.1. Institutions holding AnaptysBio Inc

Institutions are holding 134.209% of the shares of AnaptysBio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31EcoR1 Capital, LLC26.82088.6886788009466460.0844
2025-03-31First Light Asset Management, LLC15.7719.836446336023764720433.2832
2025-03-31Point72 Asset Management, L.P.8.0610.1005236837023683700
2025-03-31BlackRock Inc7.40830.00092176598-371870-14.5919
2025-03-31FMR Inc6.48440.00231905154-1125082-37.1285
2025-03-31TANG CAPITAL MANAGEMENT LLC5.25911.5891154515321427416.1002
2025-03-31Vanguard Group Inc5.16440.00051517325-326415-17.704
2025-03-31Boxer Capital Management, LLC4.42477.2689130000000
2025-03-31Sofinnova Ventures3.94831.408411600331027106772.6843
2025-03-31Bank of America Corp3.89360.0017114395911260106273.3857
2025-03-31Citigroup Inc3.64610.0102107124710174701892.017
2025-03-31Palo Alto Investors, LLC3.47413.6133102071317674220.9417
2025-03-31T. Rowe Price Associates, Inc.3.11460.0021915081-9926-1.0731
2025-03-31State Street Corp2.92960.0007860723-425032-33.057
2025-03-31Sanofi2.79759.207582191700
2025-03-31Woodline Partners LP2.69230.095679102330595063.073
2025-03-31Camber Capital Management LLC2.55270.4953750000-500000-40
2025-03-31Morgan Stanley - Brokerage Accounts1.71760.0007504636288719133.7176
2025-03-31Geode Capital Management, LLC1.67170.000749116745700.9392
2025-03-31Victory Capital Management Inc.1.38330.00774064307198021.5219
Total 113.215142.331133263225+7614232+22.9%

4.9.2. Funds holding AnaptysBio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv2.27680.000966894600
2025-03-31Fidelity Small Cap Growth2.12780.172762515500
2025-05-31iShares Russell 2000 ETF1.85790.019754585300
2025-03-31T. Rowe Price New Horizons1.85590.0629545276-7374-1.3343
2025-03-31US Small-Cap Growth II Equity Comp1.85590.0629545276-7534-1.3629
2024-12-31FIAM Small Cap Core Composite1.60340.1286471100-76700-14.0015
2025-03-31FIAM Small Cap Core CIT Cl B1.5660.205246010000
2025-05-31SPDR® S&P Biotech ETF1.22090.1735872121280.5968
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.06810.00683138125200.166
2025-03-31Fidelity Small Cap Growth K60.95410.157228030714200.5092
2025-04-30Nuveen Quant Small Cap Equity R60.94080.19952764202764200
2025-05-31Bridge Builder Small/Mid Cap Growth0.86210.063325329761702.4967
2025-05-31Franklin Biotechnology Discv A(acc)USD0.76710.400622537600
2025-03-31Fidelity Small Cap Index0.73440.01662157829070.4221
2025-05-31iShares Russell 2000 Growth ETF0.62880.037218474500
2025-03-31Victory Science & Technology0.57950.29311702462086413.9669
2025-05-31iShares Biotechnology ETF0.57070.074716768300
2025-03-31Vanguard Explorer Inv0.55860.01541641266359063.251
2025-03-31T. Rowe Price New Horizons Tr-A0.55470.06711629852100.129
2025-03-31Fidelity Series Small Cap Core0.50220.206514755293006.7268
Total 23.08572.36096782758+289921+4.3%

5.3. Insider Transactions

Insiders are holding 5.063% of the shares of AnaptysBio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-02Ecor1 Capital, LlcBUY664612.95
2024-12-30Ecor1 Capital, LlcBUY6518412.92
2024-09-23Paul F LizzulSELL150038.67
2024-09-16Dennis MulroySELL1222039.91
2024-09-16Eric J LoumeauSELL872039.82
2024-08-14Ecor1 Capital, LlcBUY27397236.5
2024-07-18Paul F LizzulSELL150035
2024-07-15Hollings RentonSELL1000030.64
2024-06-21Dennis M FentonSELL195023.17
2024-06-18Hollings RentonSELL195023.16
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets422,053
Total Liabilities388,032
Total Stockholder Equity34,021
 As reported
Total Liabilities 388,032
Total Stockholder Equity+ 34,021
Total Assets = 422,053

Assets

Total Assets422,053
Total Current Assets363,112
Long-term Assets58,941
Total Current Assets
Cash And Cash Equivalents 98,637
Short-term Investments 241,299
Net Receivables 17,884
Other Current Assets 5,292
Total Current Assets  (as reported)363,112
Total Current Assets  (calculated)363,112
+/-0
Long-term Assets
Property Plant Equipment 15,664
Long Term Investments 43,021
Long-term Assets Other 256
Long-term Assets  (as reported)58,941
Long-term Assets  (calculated)58,941
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities44,037
Long-term Liabilities343,995
Total Stockholder Equity34,021
Total Current Liabilities
Short-term Debt 1,962
Accounts payable 6,123
Other Current Liabilities 32,408
Total Current Liabilities  (as reported)44,037
Total Current Liabilities  (calculated)40,493
+/- 3,544
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt13,613
Long-term Liabilities Other 330,382
Long-term Liabilities  (as reported)343,995
Long-term Liabilities  (calculated)343,995
+/-0
Total Stockholder Equity
Common Stock30
Retained Earnings -798,656
Accumulated Other Comprehensive Income 161
Other Stockholders Equity 832,486
Total Stockholder Equity (as reported)34,021
Total Stockholder Equity (calculated)34,021
+/-0
Other
Capital Stock30
Cash and Short Term Investments 339,936
Common Stock Shares Outstanding 30,644
Current Deferred Revenue3,544
Liabilities and Stockholders Equity 422,053
Net Debt -83,062
Net Invested Capital 34,021
Net Working Capital 319,075
Property Plant and Equipment Gross 22,397
Short Long Term Debt Total 15,575



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
3,914
0
0
0
25,065
22,804
22,291
60,877
56,280
54,723
58,498
55,837
62,180
131,111
130,409
121,945
329,364
314,837
306,017
523,121
508,997
494,226
480,149
451,505
435,197
424,233
401,746
384,750
416,552
396,418
426,569
424,335
643,070
625,171
603,848
618,503
610,383
551,792
517,100
487,326
452,389
405,835
427,376
493,418
483,834
422,053
422,053483,834493,418427,376405,835452,389487,326517,100551,792610,383618,503603,848625,171643,070424,335426,569396,418416,552384,750401,746424,233435,197451,505480,149494,226508,997523,121306,017314,837329,364121,945130,409131,11162,18055,83758,49854,72356,28060,87722,29122,80425,0650003,914
   > Total Current Assets 
0
0
0
0
24,401
22,104
21,077
58,240
53,464
51,379
55,090
52,352
58,208
110,155
115,848
120,327
252,696
251,945
271,819
503,022
434,216
421,942
430,988
424,597
377,733
371,055
384,516
345,814
396,561
387,131
398,061
386,644
553,876
512,411
452,809
450,444
447,205
437,154
438,535
428,000
406,835
372,420
367,350
448,681
431,876
363,112
363,112431,876448,681367,350372,420406,835428,000438,535437,154447,205450,444452,809512,411553,876386,644398,061387,131396,561345,814384,516371,055377,733424,597430,988421,942434,216503,022271,819251,945252,696120,327115,848110,15558,20852,35255,09051,37953,46458,24021,07722,10424,4010000
       Cash And Cash Equivalents 
2,810
0
0
0
22,188
19,607
16,894
55,245
51,684
49,318
50,586
47,134
51,232
96,754
30,752
26,669
81,189
69,474
57,057
293,408
113,596
105,853
146,552
182,898
171,017
165,317
221,172
209,154
250,456
284,148
332,254
336,328
495,729
166,412
71,701
58,547
71,308
94,562
35,206
26,295
35,965
53,695
71,821
191,581
123,080
98,637
98,637123,080191,58171,82153,69535,96526,29535,20694,56271,30858,54771,701166,412495,729336,328332,254284,148250,456209,154221,172165,317171,017182,898146,552105,853113,596293,40857,05769,47481,18926,66930,75296,75451,23247,13450,58649,31851,68455,24516,89419,60722,1880002,810
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
6,742
6,742
0
6,742
75,607
89,053
167,218
178,691
210,852
200,406
313,486
309,812
275,664
238,104
203,210
197,166
156,706
129,192
143,197
96,212
58,597
37,736
52,368
339,209
370,450
384,419
369,933
336,589
394,280
386,752
354,939
300,970
278,983
238,536
262,293
241,299
241,299262,293238,536278,983300,970354,939386,752394,280336,589369,933384,419370,450339,20952,36837,73658,59796,212143,197129,192156,706197,166203,210238,104275,664309,812313,486200,406210,852178,691167,21889,05375,6076,74206,7426,7420000000000
       Net Receivables 
0
0
0
0
1,455
1,597
2,757
1,913
1,226
1,191
3,578
4,153
5,343
4,965
5,637
1,486
1,601
1,610
152
5,173
174
175
5,000
0
0
5,000
0
0
0
1,247
642
761
876
921
1,033
1,180
1,419
1,523
3,182
3,269
6,851
7,089
9,007
12,195
40,765
17,884
17,88440,76512,1959,0077,0896,8513,2693,1821,5231,4191,1801,0339218767616421,2470005,000005,0001751745,1731521,6101,6011,4865,6374,9655,3434,1533,5781,1911,2261,9132,7571,5971,4550000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60
60
60
-876
0
0
0
0
0
0
0
0
0
0
-12,195
0
0
00-12,1950000000000-87660606000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
664
700
1,214
2,637
2,816
3,344
3,408
3,485
3,972
20,956
14,561
1,618
76,668
62,892
34,198
20,099
74,781
72,284
49,161
26,908
57,464
53,178
17,230
38,936
19,991
9,287
28,508
37,691
89,194
112,760
151,039
168,059
163,178
114,638
78,565
59,326
45,554
33,415
60,026
44,737
51,958
58,941
58,94151,95844,73760,02633,41545,55459,32678,565114,638163,178168,059151,039112,76089,19437,69128,5089,28719,99138,93617,23053,17857,46426,90849,16172,28474,78120,09934,19862,89276,6681,61814,56120,9563,9723,4853,4083,3442,8162,6371,2147006640000
       Property Plant Equipment 
750
0
0
0
579
615
588
564
551
536
483
425
471
569
543
513
665
659
1,086
1,344
1,445
1,584
1,481
1,695
1,618
1,610
1,495
1,585
1,783
1,754
22,766
22,191
21,841
21,309
20,798
20,292
19,987
19,453
19,070
18,867
18,272
17,686
17,124
16,567
16,232
15,664
15,66416,23216,56717,12417,68618,27218,86719,07019,45319,98720,29220,79821,30921,84122,19122,7661,7541,7831,5851,4951,6101,6181,6951,4811,5841,4451,3441,086659665513543569471425483536551564588615579000750
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
20,327
20,327
0
20,327
13,912
999
75,897
61,884
32,730
18,616
73,128
68,551
45,707
23,418
54,305
50,215
14,321
36,177
17,546
7,056
5,484
15,242
67,097
91,195
129,985
147,511
142,935
94,929
59,239
40,203
27,026
15,473
42,646
27,914
35,470
43,021
43,02135,47027,91442,64615,47327,02640,20359,23994,929142,935147,511129,98591,19567,09715,2425,4847,05617,54636,17714,32150,21554,30523,41845,70768,55173,12818,61632,73061,88475,89799913,91220,327020,32720,3270000000000
       Long-term Assets Other 
0
0
0
0
85
85
626
2,073
2,265
2,808
2,925
3,060
3,501
60
106
106
106
349
382
139
208
2,149
1,973
1,795
1,541
1,353
1,414
1,174
662
477
258
258
256
256
256
256
256
256
256
256
256
256
256
256
256
256
2562562562562562562562562562562562562562562582584776621,1741,4141,3531,5411,7951,9732,149208139382349106106106603,5013,0602,9252,8082,2652,07362685850000
> Total Liabilities 
3,769
0
0
0
19,072
15,912
16,438
15,296
13,943
12,944
14,102
11,080
22,912
20,996
21,234
20,590
21,783
20,310
21,038
23,444
22,632
26,071
31,728
30,613
30,189
23,669
20,310
24,507
19,821
14,475
40,838
40,727
286,642
294,424
299,542
340,884
348,280
360,699
368,650
366,943
364,286
358,057
417,497
409,051
412,966
388,032
388,032412,966409,051417,497358,057364,286366,943368,650360,699348,280340,884299,542294,424286,64240,72740,83814,47519,82124,50720,31023,66930,18930,61331,72826,07122,63223,44421,03820,31021,78320,59021,23420,99622,91211,08014,10212,94413,94315,29616,43815,91219,0720003,769
   > Total Current Liabilities 
3,162
0
0
0
11,681
11,284
10,479
9,643
7,376
7,114
8,829
7,539
5,708
8,126
10,079
11,174
14,090
14,343
16,790
20,873
21,836
24,754
30,623
29,730
29,535
23,250
20,130
24,474
19,821
14,475
20,616
20,889
16,099
19,781
19,871
21,063
26,054
35,795
41,631
39,178
37,442
32,298
40,420
43,880
45,428
44,037
44,03745,42843,88040,42032,29837,44239,17841,63135,79526,05421,06319,87119,78116,09920,88920,61614,47519,82124,47420,13023,25029,53529,73030,62324,75421,83620,87316,79014,34314,09011,17410,0798,1265,7087,5398,8297,1147,3769,64310,47911,28411,6810003,162
       Short-term Debt 
0
0
0
0
129
251
769
1,151
21
407
996
1,596
1
1,250
3,125
5,013
6,892
7,522
7,527
7,548
7,632
7,282
5,600
3,922
2,246
898
925
851
342
197
1,110
2,194
3,010
3,074
3,140
3,208
3,274
3,342
3,412
3,482
3,554
1,813
3,700
3,774
1,925
1,962
1,9621,9253,7743,7001,8133,5543,4823,4123,3423,2743,2083,1403,0743,0102,1941,1101973428519258982,2463,9225,6007,2827,6327,5487,5277,5226,8925,0133,1251,25011,596996407211,1517692511290000
       Short Long Term Debt 
0
0
0
0
4,793
0
0
0
4,903
0
985
1,590
13,809
1,250
14,112
5,000
6,875
7,500
7,500
7,500
7,574
6,488
4,781
3,077
1,375
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,3753,0774,7816,4887,5747,5007,5007,5006,8755,00014,1121,25013,8091,59098504,9030004,7930000
       Accounts payable 
197
0
0
0
415
657
765
1,561
1,521
663
2,060
1,440
2,278
2,546
3,724
2,557
2,323
2,416
4,426
6,180
5,443
9,072
10,921
10,522
16,237
8,571
6,289
5,484
4,217
2,452
4,103
5,717
1,741
2,481
1,587
3,006
2,784
3,168
4,761
6,521
4,698
4,582
4,890
3,592
4,002
6,123
6,1234,0023,5924,8904,5824,6986,5214,7613,1682,7843,0061,5872,4811,7415,7174,1032,4524,2175,4846,2898,57116,23710,52210,9219,0725,4436,1804,4262,4162,3232,5573,7242,5462,2781,4402,0606631,5211,561765657415000197
       Other Current Liabilities 
2,147
0
0
0
1,052
10,376
1,550
2,111
2,753
2,779
2,890
2,974
3,429
4,330
3,230
3,604
4,875
4,405
4,837
7,145
8,761
8,400
14,102
15,286
11,052
13,781
12,916
18,139
15,262
11,826
15,403
12,978
11,348
14,226
15,144
14,849
19,996
29,285
33,458
29,175
29,190
25,903
31,830
36,514
39,501
32,408
32,40839,50136,51431,83025,90329,19029,17533,45829,28519,99614,84915,14414,22611,34812,97815,40311,82615,26218,13912,91613,78111,05215,28614,1028,4008,7617,1454,8374,4054,8753,6043,2304,3303,4292,9742,8902,7792,7532,1111,55010,3761,0520002,147
   > Long-term Liabilities 
0
0
0
0
7,391
4,628
5,959
5,653
6,567
5,830
5,273
3,541
17,204
12,870
11,155
9,416
7,693
5,967
4,248
2,571
796
1,317
1,105
883
654
419
180
33
0
0
20,222
19,838
270,543
274,643
279,671
319,821
322,226
324,904
327,019
327,765
326,844
325,759
377,077
365,171
367,538
343,995
343,995367,538365,171377,077325,759326,844327,765327,019324,904322,226319,821279,671274,643270,54319,83820,22200331804196548831,1051,3177962,5714,2485,9677,6939,41611,15512,87017,2043,5415,2735,8306,5675,6535,9594,6287,3910000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
12,709
10,987
9,269
7,553
5,834
4,120
2,409
625
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000006252,4094,1205,8347,5539,26910,98712,7090000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-129
-251
-769
-1,151
-21
-407
-996
-1,596
-1
-1,250
-3,125
-5,013
-6,892
-7,522
-7,527
-7,548
-7,632
-7,282
-5,600
-3,922
-2,246
0
0
33
0
0
19,667
18,741
17,945
17,522
17,082
16,631
16,176
15,717
15,240
14,752
14,260
15,575
13,246
12,720
14,112
13,613
13,61314,11212,72013,24615,57514,26014,75215,24015,71716,17616,63117,08217,52217,94518,74119,667003300-2,246-3,922-5,600-7,282-7,632-7,548-7,527-7,522-6,892-5,013-3,125-1,250-1-1,596-996-407-21-1,151-769-251-1290000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
161
168
147
140
133
128
162
171
1,317
1,105
883
654
419
180
33
0
0
0
0
251,093
255,584
261,019
301,586
304,413
307,516
310,073
311,272
310,807
310,184
361,981
350,564
353,426
330,382
330,382353,426350,564361,981310,184310,807311,272310,073307,516304,413301,586261,019255,584251,0930000331804196548831,1051,3171711621281331401471681610000000000000
       Deferred Long Term Liability 
0
0
0
0
2,029
0
0
0
2,205
0
138
148
3,441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000003,44114813802,2050002,0290000
> Total Stockholder Equity
145
0
0
0
5,993
6,892
5,853
45,581
42,337
41,779
44,396
44,757
39,268
110,115
109,175
101,355
307,581
294,527
284,979
499,677
486,365
468,155
448,421
420,892
405,008
400,564
381,436
360,243
396,731
381,943
385,731
383,608
356,428
330,747
304,306
277,619
262,103
191,093
148,450
120,383
88,103
47,778
9,879
84,367
70,868
34,021
34,02170,86884,3679,87947,77888,103120,383148,450191,093262,103277,619304,306330,747356,428383,608385,731381,943396,731360,243381,436400,564405,008420,892448,421468,155486,365499,677284,979294,527307,581101,355109,175110,11539,26844,75744,39641,77942,33745,5815,8536,8925,993000145
   Common Stock
17
0
0
0
17
18
18
18
3
18
18
14
3
20
20
20
24
24
24
27
27
27
27
27
27
27
27
27
27
27
27
27
28
28
28
28
29
27
27
27
27
27
27
30
30
30
303030272727272727292828282827272727272727272727272727242424202020314181831818181700017
   Retained Earnings Total Equity0000000-534,577-494,732-450,477-424,064-390,562-358,008-321,753-289,215-282,549-282,120-263,957-297,603-273,836-252,288-244,026-223,763-192,730-168,768-146,690-129,696-113,738-100,100-85,000-78,173-69,083-66,4000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-3,355
0
-3,497
-3,560
-3,583
-3,640
-3,700
-3,758
-3,798
-13
-59
-43
-426
-801
-677
-541
-223
204
574
480
338
1,145
753
259
-4
-111
-176
-200
-422
-2,434
-3,861
-6,007
-5,246
-3,267
-3,611
-2,350
-797
-624
-415
759
305
161
161305759-415-624-797-2,350-3,611-3,267-5,246-6,007-3,861-2,434-422-200-176-111-42597531,145338480574204-223-541-677-801-426-43-59-13-3,798-3,758-3,700-3,640-3,583-3,560-3,4970-3,3550000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
176,507
178,297
179,551
393,017
395,424
399,370
629,887
633,251
636,692
640,550
644,148
648,669
651,680
654,492
657,560
660,665
664,147
668,429
672,996
678,575
691,161
698,701
707,662
717,797
689,065
686,611
0
0
0
0
0
0
0
0000000686,611689,065717,797707,662698,701691,161678,575672,996668,429664,147660,665657,560654,492651,680648,669644,148640,550636,692633,251629,887399,370395,424393,017179,551178,297176,5070000000000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
17,777
14,499
18,194
18,759
19,065
19,437
19,792
95,099
16,672
176,507
178,297
179,551
393,017
395,424
399,370
629,887
633,251
636,692
640,550
644,148
648,669
651,680
654,492
657,560
660,665
664,147
668,429
672,996
678,575
691,161
698,701
707,662
717,797
689,065
686,611
694,591
702,969
706,407
714,959
821,121
829,860
832,486
832,486829,860821,121714,959706,407702,969694,591686,611689,065717,797707,662698,701691,161678,575672,996668,429664,147660,665657,560654,492651,680648,669644,148640,550636,692633,251629,887399,370395,424393,017179,551178,297176,50716,67295,09919,79219,43719,06518,75918,19414,49917,7770000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue91,280
Cost of Revenue-2,397
Gross Profit88,88388,883
 
Operating Income (+$)
Gross Profit88,883
Operating Expense-206,229
Operating Income-114,949-117,346
 
Operating Expense (+$)
Research Development163,840
Selling General Administrative42,389
Selling And Marketing Expenses0
Operating Expense206,229206,229
 
Net Interest Income (+$)
Interest Income19,794
Interest Expense-50,087
Other Finance Cost-0
Net Interest Income-30,293
 
Pretax Income (+$)
Operating Income-114,949
Net Interest Income-30,293
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-145,228-84,670
EBIT - interestExpense = -145,228
-145,228
-95,144
Interest Expense50,087
Earnings Before Interest and Taxes (EBIT)-95,141-95,141
Earnings Before Interest and Taxes (EBITDA)-92,744
 
After tax Income (+$)
Income Before Tax-145,228
Tax Provision-3
Net Income From Continuing Ops-145,231-145,231
Net Income-145,231
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses206,229
Total Other Income/Expenses Net-30,27930,293
 

Technical Analysis of Anaptysbio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anaptysbio. The general trend of Anaptysbio is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anaptysbio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Anaptysbio Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AnaptysBio Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 24.68 < 25.88 < 26.51.

The bearish price targets are: 19.93 > 19.45 > 19.04.

Know someone who trades $ANAB? Share this with them.👇

AnaptysBio Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AnaptysBio Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AnaptysBio Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AnaptysBio Inc. The current macd is 0.36388959.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anaptysbio price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Anaptysbio. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Anaptysbio price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
AnaptysBio Inc Daily Moving Average Convergence/Divergence (MACD) ChartAnaptysBio Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AnaptysBio Inc. The current adx is 20.82.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Anaptysbio shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
AnaptysBio Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AnaptysBio Inc. The current sar is 20.15.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AnaptysBio Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AnaptysBio Inc. The current rsi is 51.24. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
AnaptysBio Inc Daily Relative Strength Index (RSI) ChartAnaptysBio Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AnaptysBio Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anaptysbio price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
AnaptysBio Inc Daily Stochastic Oscillator ChartAnaptysBio Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AnaptysBio Inc. The current cci is -64.62147626.

AnaptysBio Inc Daily Commodity Channel Index (CCI) ChartAnaptysBio Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AnaptysBio Inc. The current cmo is -4.32235151.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
AnaptysBio Inc Daily Chande Momentum Oscillator (CMO) ChartAnaptysBio Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AnaptysBio Inc. The current willr is -73.91217098.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Anaptysbio is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AnaptysBio Inc Daily Williams %R ChartAnaptysBio Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AnaptysBio Inc.

AnaptysBio Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AnaptysBio Inc. The current atr is 1.39372818.

AnaptysBio Inc Daily Average True Range (ATR) ChartAnaptysBio Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AnaptysBio Inc. The current obv is 1,835,851.

AnaptysBio Inc Daily On-Balance Volume (OBV) ChartAnaptysBio Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AnaptysBio Inc. The current mfi is 45.30.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
AnaptysBio Inc Daily Money Flow Index (MFI) ChartAnaptysBio Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AnaptysBio Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

AnaptysBio Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AnaptysBio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.241
Ma 20Greater thanMa 5023.074
Ma 50Greater thanMa 10021.692
Ma 100Greater thanMa 20019.548
OpenGreater thanClose22.020
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Anaptysbio with someone you think should read this too:
  • Are you bullish or bearish on Anaptysbio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anaptysbio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AnaptysBio Inc

I send you an email if I find something interesting about AnaptysBio Inc.


Comments

How you think about this?

Leave a comment

Stay informed about AnaptysBio Inc.

Receive notifications about AnaptysBio Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.